A Randomised, Double Blind, Placebo-controlled, Three Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Inhaled RV1729 in Healthy Subjects and Subjects With Mild to Moderate Asthma

Trial Profile

A Randomised, Double Blind, Placebo-controlled, Three Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Inhaled RV1729 in Healthy Subjects and Subjects With Mild to Moderate Asthma

Completed
Phase of Trial: Phase I

Latest Information Update: 14 May 2014

At a glance

  • Drugs RV 1729 (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors RespiVert
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Oct 2013 Planned End Date changed from 1 Dec 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top